Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (AVIR) is a clinical-stage biopharmaceutical company pioneering oral antiviral therapies for severe viral diseases. This page provides investors and healthcare professionals with timely updates on clinical trial progress, regulatory milestones, and corporate developments.
Key resources include: Press releases detailing study results, partnership announcements with research institutions, and financial disclosures. Track updates on COVID-19 therapeutic candidates, hepatitis C treatments, and emerging programs targeting RNA viruses.
All content is sourced directly from company filings and official communications to ensure accuracy. Visitors can expect detailed coverage of Phase 2/3 trial outcomes, FDA interactions, and strategic initiatives advancing antiviral drug development.
Bookmark this page for consolidated access to AVIR's latest scientific advancements and business updates. Check regularly for new developments from Atea's nucleos(t)ide prodrug platform and pipeline expansion efforts.
Atea Pharmaceuticals (AVIR) announced promising interim Phase 2 results for AT-527, a COVID-19 treatment, showing rapid viral load decrease in hospitalized patients. The active metabolite achieved target antiviral levels in lung fluid, critical for effective treatment. Collaboration with Roche continues, facilitating multiple ongoing clinical studies. Financially, Q2 2021 collaboration revenue reached $60.4 million, with a net income of $1.5 million, significantly improving from a loss in the previous year. Cash reserves stand at $816.5 million, reflecting strong financial backing for ongoing development.
Atea Pharmaceuticals (Nasdaq: AVIR) announced a live conference call and audio webcast on August 12, 2021, at 4:30 p.m. ET to discuss its second-quarter financial results and provide a clinical update. The call can be accessed via phone or through the company's website. Atea focuses on developing oral therapeutics for severe viral infections, utilizing a proprietary nucleotide prodrug platform for treating viruses such as SARS-CoV-2, HCV, and RSV. For more information, visit Atea Pharmaceuticals.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi and the management team will participate in a fireside chat at the William Blair Biotech Focus Conference on July 15, 2021, at 12:00 p.m. ET. A live webcast will be available on Atea's website, with a replay accessible for 90 days post-event.
Atea is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for severe viral infections, including COVID-19, using its proprietary nucleotide prodrug platform.
Atea Pharmaceuticals announced promising interim results from its global Phase 2 study of AT-527, an oral antiviral for COVID-19, showing significant viral load reductions in hospitalized patients. In 70 high-risk patients, those receiving AT-527 exhibited an 80% greater mean reduction in viral load by Day 2 compared to placebo. Clearance of SARS-CoV-2 was observed in 47% of patients by Day 14. AT-527 demonstrated a favorable safety profile with no drug-related serious adverse events. Ongoing trials include Phase 2 MOONSONG and Phase 3 MORNINGSKY, with more results expected in 2021.
Atea Pharmaceuticals (Nasdaq: AVIR) has achieved a significant milestone by securing a $50 million payment under its license agreement with Roche for the development of AT-527, an oral antiviral for COVID-19. This payment reflects the ongoing collaboration and progress in clinical trials, including the global Phase 3 MORNINGSKY trial. Atea retains commercialization rights in the U.S., while Roche holds them outside the U.S. AT-527 is designed to minimize viral replication and could be used in both pre- and post-exposure prophylactic settings.
Atea Pharmaceuticals has appointed Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Previously at Gilead Sciences, Dr. Avila brings significant experience in medical affairs focusing on COVID-19 and other viral diseases. CEO Jean-Pierre Sommadossi expressed confidence in Dr. Avila’s expertise to enhance Atea’s capabilities, particularly in advancing its antiviral pipeline, including AT-527 for COVID-19. Atea aims to develop innovative oral therapeutics for severe viral infections, leveraging its proprietary nucleotide prodrug platform.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that its CEO, Jean-Pierre Sommadossi, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. ET. The presentation will include insights into Atea's focus on developing oral therapeutics for severe viral infections, particularly for ssRNA viruses like SARS-CoV-2, the virus causing COVID-19. A live webcast of the event can be accessed here. A replay will be available for 90 days.
Atea Pharmaceuticals has appointed Jerome Adams, M.D., M.P.H., former U.S. Surgeon General, to its Board of Directors. Dr. Adams brings extensive experience in clinical practice, public health, and leadership roles, particularly during the COVID-19 pandemic. His expertise will support Atea's ongoing global Phase 3 clinical trial for AT-527, an oral antiviral aimed at treating COVID-19. Atea focuses on developing innovative therapies for severe viral infections, leveraging its proprietary nucleotide prodrug platform.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) recently reported its financial results for Q1 2021, highlighting a net income of $30.7 million, a significant turnaround from a net loss of $4.0 million in Q1 2020. The rise was primarily driven by $66.0 million in collaboration revenue from its Roche License Agreement. Atea initiated the global Phase 3 MORNINGSKY trial for AT-527, aimed at treating COVID-19, with expected enrollment of up to 1,400 patients. Additionally, enrollment is advancing for the Phase 1a trial of AT-752 for dengue fever, showcasing Atea's commitment to tackling infectious diseases.
Atea Pharmaceuticals (Nasdaq: AVIR) announced a live conference call on May 13, 2021, at 4:30 p.m. ET to discuss its Q1 2021 financial results and provide a corporate update. The call will be accessible via a domestic and international dialing option, and an audio webcast will be available on Atea's website. The company focuses on developing antiviral therapies for life-threatening viral diseases, including COVID-19, dengue, hepatitis C, and respiratory syncytial virus, utilizing its proprietary nucleotide prodrug platform.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
